[FOR IMMEDIATE RELEASE]
NEW YORK, NY
MARCH 18, 2022

NEW YORK, March 18, 2022 – Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology, today shared preclinical data on ISB 1442, a first-in-class bispecific antibody for relapsed/refractory multiple myeloma and other CD38 positive hematologic malignancies, at the Immuno-Oncology 360 (IO360) conference. President and Chief Executive Officer of Ichnos, Cyril Konto, M.D., shared the data in a presentation titled “Beyond the T cell: Co-targeting CD38 and CD47 with a 2+1 Biparatopic Multispecific Antibody” during an afternoon session of the conference.

In addition to presenting data for ISB 1442, Dr. Konto provided a description of Ichnos’ proprietary BEAT^® platform¹ to meeting attendees. More specifically, he shared in vivo and in vitro study results showing the potency and anti-tumor effects of ISB 1442 relative to clinical benchmarks, daratumumab and agrolimab, and highlighted the flexibility of BEAT^®, which utilizes advanced heavy chain pairing and a common light chain, allows for modulation of the Fc functionality, and enables the exploration of the full design space.

The IO360 Conference is an annual gathering that convenes stakeholders from across the scientific and business communities, providing a forum to share the latest innovations in immuno-oncology. Ichnos was pleased to be a part of the agenda, which also included presentations by institutions such as John’s Hopkins University and several Fortune 100 pharmaceutical companies.

“Events such as IO360 are a great opportunity to learn about the latest in immuno-oncology and to exchange ideas with colleagues across the field,” said Dr. Konto. “I am pleased to have had the opportunity to present data on ISB 1442, and Ichnos’ proprietary BEAT platform at the meeting.”

About Ichnos Sciences Inc.

A fully integrated, global biotech with the spirit of a start-up, Ichnos is shifting the way the world thinks about innovation in medicine through its research and development of transformative, disease-centric treatments in oncology and autoimmune diseases. The company, with headquarters in New York, N.Y., is rapidly advancing a clinical-stage pipeline of novel, first-in-class candidates designed to address complex diseases and to treat patients holistically. With its patented BEAT^® technology platform, along with pioneering teams at two locations in Switzerland, Ichnos Sciences has a mission to provide breakthrough, curative therapies that will extend and improve lives, writing a new chapter in healthcare.

CONTACT

Grace Maguire
Head of Communications and Corporate Affairs
Ichnos Sciences
Corporate.Communications@ichnossciences.com

¹ Bispecific Engagement by Antibodies based on the TCR